Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported first-nine-month 2026 revenue of $3.238 billion, up 22% year over year, and adjusted operating profit of $1.108 billion, up 9%; management maintained full-year revenue guidance of $4.325 billion-$4.525 billion and expects results in the upper part of the range. EPKINLY sales rose 47% to $491 million, while management highlighted positive Phase III readouts for EPKINLY, Rina-S and petosemtamab and reiterated sales targets of more than $3 billion, more than $2 billion and $1 billion by 2029, respectively. The company has $4.992 billion in borrowings and targets gross leverage below 3x by end-2027. Risks include patent-infringement claims by Chugai concerning EPKINLY activities in Japan and an AbbVie complaint alleging trade-secret misappropriation related to Rina-S and other pipeline products.

Analysis

GMAB’s clinical pipeline has shifted from a story about promising assets to one with pivotal readouts, but the market may be moving faster than the earnings. The key second-order issue is timing: launch preparation and broader trials consume cash before approvals and meaningful sales, while a higher normalized tax rate could dilute reported EPS even if operating profit grows. The leverage target therefore depends on execution, not just pipeline value.

The growth base is improving, but not yet fully diversified: substantial incremental revenue still depends on the DARZALEX royalty stream. That leaves GMAB exposed to JNJ franchise performance and royalty-duration risk even as EPKINLY scales. For EPKINLY, earlier-line adoption is the major value inflection; Roche’s competing regimen and established treatment habits are the practical constraints, particularly outside academic centers. Rina-S and petosemtamab add upside, but management peak-sales claims remain unverified commercial scenarios, not near-term earnings estimates.

The near-term catalyst is fuller disclosure of the phase III datasets, including safety and follow-up; the December 16 R&D event is a potential information catalyst. In 1–3 months, watch regulatory engagement and the next petosemtamab readout expected in Q1 2027. Over 6–18 months, approval timing, launch uptake, and cash conversion matter more than headline hazard ratios. Chugai’s Japan patent suit and AbbVie’s trade-secret complaint create asymmetric legal overhangs; outcomes and any effect on launches or collaboration economics need verification. The contrarian risk is that investors capitalize multiple future blockbusters before proving access, pricing, and durable treatment use.

Key Decisions for Investors

• Prefer a staged, catalyst-driven long in GMAB over chasing the initial clinical-data reaction: add only after reviewing full trial data and regulatory context. Keep sizing constrained until launch economics and legal exposure are clearer; no valuation or price-level data here supports a target.
• Treat the December 16 R&D update and Q1 2027 petosemtamab milestone as re-underwriting events. Falsify the bullish thesis if full datasets materially weaken efficacy or reveal a meaningful safety burden, or if regulatory feedback delays a filing.
• Monitor whether GMAB can fund launch investment while progressing toward its leverage commitment. A missed operating-profit trajectory, slower-than-expected deleveraging, or a sharp upward revision in normalized tax assumptions would weaken the equity case.
• Track EPKINLY ordering and uptake by treatment setting, alongside Roche’s competing DLBCL data. If adoption remains concentrated in existing indications rather than broadening into earlier lines, reduce the assumed pipeline-to-revenue conversion.